References
- News-Medical.Net . Researchers receive £230,000 to develop world's first smart vaccine device. www.news-medical.net/news/20210106/Researchers-receive-c2a3230000-to-develop-worlds-first-smart-vaccine-device.aspx
- Nguyen TT , OhY , KimYet al. Progress in microneedle array patch (MAP) for vaccine delivery. Human Vaccines & Immunotherapeutics17(1), 316–327 doi:10.1080/21645515.2020.1767997.
- Johnson and Johnson press release . Johnson & Johnson announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its Phase III ENSEMBLE trial. www.jnj.com/johnson-and-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-end points-in-interim-analysis-of-its-phase-3-ensemble-trial.
- Novavax press release . Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK Phase III trial. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3
- Lilly press release . Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents. http://lilly.mediaroom.com/2021-01-21-Lillys-neutralizing-antibody-bamlanivimab-LY-CoV555-prevented-COVID-19-at-nursing-homes-in-the-BLAZE-2-trial-reducing-risk-by-up-to-80-percent-for-residents.
- Sanofi press release . Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40. www.sanofi.com/en/media-room/press-releases/2021/2021-01-11-08-30-00
- Gilead press release . Gilead and Vir Biotechnology establish clinical collaboration to explore combination strategies for functional cure for chronic hepatitis B virus. www.gilead.com/news-and-press/press-room/press-releases/2021/1/gilead-and-vir-biotechnology-establish-clinical-collaboration-to-explore-combination-strategies-for-functional-cure-for-chronic-hepatitis-b-virus.
- Merck press release . Merck acquires AmpTec to expand mRNA capabilities for vaccines, treatments and diagnostics. www.merckgroup.com/en/news/amptec-acquisition-07-01-2021.html
- Business Wire . Credence Medsystems receives a strategic investment from one of the world’s leading pharmaceutical companies.www.businesswire.com/news/home/20210125005138/en/
- Business Wire . Amneal to acquire substantially all of Kashiv Specialty Pharmaceuticals. www.businesswire.com/news/home/20210112005318/en/Amneal-to-Acquire-Substantially-All-of-Kashiv-Specialty-Pharmaceuticals/
- GlaxoSmithKline plc press release . ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment. www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-fda-approval-of-cabenuva-cabotegravir-rilpivirine-the-first-and-only-complete-long-acting-regimen-for-hiv-treatment/.
- Business Wire . Lyndra Therapeutics announces first subjects dosed in Phase I clinical trial of once-weekly rosuvastatin extended-release capsule, LYN-047. www.businesswire.com/news/home/20210121005258/en/Lyndra-Therapeutics-Announces-First-Subjects-Dosed-in-Phase-1-Clinical-Trial-of-Once-Weekly-Rosuvastatin-Extended-Release-Capsule-LYN-047.
- Business Wire . Glaukos' iDose® TR demonstrates sustained IOP reduction and favorable safety profile over 24 months in Phase IIb study. www.businesswire.com/news/home/20210113005174/en/Glaukos%E2%80%99-iDose%C2%AE-TR-Demonstrates-Sustained-IOP-Reduction-and-Favorable-Safety-Profile-Over-24-Months-in-Phase-2b-Study/.
- Biohaven Pharmaceuticals press release . Biohaven provides update on Phase II/III trial and Alzheimer’s disease program. www.biohavenpharma.com/investors/news-events/press-releases/01-18-2021
- Biogen press release . Biogen and Eisai announce FDA’s 3-month extension of review period for the biologics license application for aducanumab. https://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-announce-fdas-3-month-extension-review-period.
- University of Oxford press release . Investigating new treatment for schizophrenia. www.medsci.ox.ac.uk/news/investigating-new-treatment-for-schizophrenia.
- Nanoparticle drug delivery technique shows promise for treating pancreatic cancer, American Association for the Advancement of Science (AAAS), Eurekalert. www.eurekalert.org/pub_releases/2021-01/varc-ndd012821.php.
- Ray P , DuttaD , HaqueI , QuadirMet al. pH-Sensitive nanodrug carriers for codelivery of ERK inhibitor and gemcitabine enhance the inhibition of tumor growth in pancreatic cancer. Mol. Pharm.18(1), 87–100 (2021).
- Nanoparticle drug-delivery system developed to treat brain disorders lab news. www.labnews.co.uk/article/2031051/nanoparticle-drug-delivery-system-developed-to-treat-brain-disorders
- Li W , QiuJ , LiX-Let al. BBB pathophysiology – independent delivery of siRNA in traumatic brain injury. Sci. Adv. (2020) doi:10.1126/sciadv.abd6889.
- Cambridge Quantum Computing news release . Cambridge Quantum to develop quantum algorithms with Roche for drug discovery & development. https://cambridgequantum.com/wp-content/uploads/2021/01/CQC_Roche_28012021.pdf
- Boston Consulting Group news article . Will Quantum Computing transform biopharma R&D?, BCG. www.bcg.com/publications/2019/quantum-computing-transform-biopharma-research-development